Boehringer Ingelheim sees new alternatives in most cancers therapy by way of American Nerio Therapeutics’ checkpoint inhibitors, and the acquisition consists of the acquisition of a preclinical molecule.
发布者:BY ULRICH QUISTGAARD,转转请注明出处:https://robotalks.cn/boehringer-ingelheim-acquires-us-cancer-company-in-usd-1-3-billion-deal/